DRUG-ELUTING STENTS MARKET

INTRODUCTION TODRUG-ELUTING STENTS MARKET

Drug-eluting stents (DES) have revolutionized the field of interventional cardiology, significantly improving  outcomes for patients with coronary artery disease. These innovative medical devices are used to restore blood flow through blocked or narrowed coronary arteries while  delivering medications to prevent restenosis or the recurrence of blocked arteries.

Because of their unique design and ability to deliver drugs, drug-eluting stents have become the standard of care for coronary artery disease.   A drug-eluting stent is a small metal mesh tube, usually made of a biocompatible material such as stainless steel or a cobalt-chromium alloy.

The stent is attached to a deflated balloon catheter that is inserted into the narrowed coronary artery during a minimally invasive procedure called percutaneous coronary intervention (PCI) or angioplasty. When the stent reaches its destination, the balloon inflates, expanding the stent and pushing it against the walls of the artery, effectively widening the artery and restoring blood flow. 

 Drug-eluting stents are distinguished from bare-metal stents (BMS) by their ability to deliver medication directly to the arterial occlusion. The mesh structure of the stent is coated with a polymer containing anti-restenotic drugs.

These drugs are slowly released into the surrounding arterial tissue over time, preventing the proliferation of smooth muscle cells and reducing the likelihood of restenosis. Commonly used drugs in drug-eluting stents are sirolimus, paclitaxel, everolimus, and zotarolimus.

The use of drug-eluting stents has shown significant advantages over bare metal stents. Clinical studies have shown that drug-eluting stents reduce the incidence of restenosis and the need for repeat procedures, such as repeat angioplasty or coronary  bypass grafting.

By preventing restenosis, these stents help maintain the improved blood flow achieved during the initial procedure, reducing the risk of repeat heart attacks and improving long-term patient outcomes. 

 The introduction of drug-eluting stents has also significantly reduced the incidence of in-stent thrombosis, a potential complication in which blood clots form inside the stent.

This is because of the antiplatelet medication regimen that patients receiving a drug-eluting stent must follow for a period of time after the procedure. Antiplatelet medications such as aspirin and P2Y12 inhibitors (eg, clopidogrel, ticagrelor) help prevent blood clots and reduce the risk of stent thrombosis.  

 The development of drug-eluting stents has been accompanied by continuous improvements in stent design and drug delivery technology. Newer generations of drug-eluting stents have thinner struts, which are the frame-like elements that make up the stent.

Thinner struts reduce the profile of the stent, making tortuous arteries easier to navigate and potentially reducing the risk of vascular injury. In addition, advances in polymer coatings and drug release kinetics have improved drug delivery efficiency and reduced the potential for inflammation or side effects. Although drug-eluting stents have revolutionized the treatment of coronary artery disease, they are not without limitations.

Late stent thrombosis, although rare, remains a concern, particularly in patients who  discontinue  antiplatelet medications prematurely. Additionally, the long-term effects of drug-eluting stents on arterial healing and  potential  late complications are areas of ongoing investigation and research. 

 In conclusion, drug-eluting stents have revolutionized the treatment of coronary artery disease by combining mechanical intervention with targeted drug delivery.

These stents effectively restore blood flow through narrowed arteries while providing anti-restenosis medication to prevent the arteries from clogging. The use of drug-eluting stents has shown superior results compared to bare metal stents, reducing the need for repeat procedures and improving long-term patient outcomes.

Continued advances in stent design and drug delivery technology continue to improve the efficacy and safety of these innovative medical devices. With further research and development, drug-eluting stents  promise  even greater advances in the treatment of coronary artery disease.

DRUG-ELUTING STENTS MARKET SIZE AND FORECAST

The Global Drug-Eluting Stents Market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.

DRUG-ELUTING STENTS MARKETNEW PRODUCT LAUNCH

1. Abluminus DES

 Abluminus DES is a drug-eluting stent that uses a polymer-based delivery mechanism to deliver everolimus to the coronary artery. Everolimus is a powerful immunosuppressant that helps  prevent  scar tissue from forming around the stent, which can lead to restenosis.  Abluminus DES has been shown in clinical trials to effectively reduce the risk of restenosis. 

2. Abluminus NP

 Abluminus NP is a drug-eluting stent that uses a polymer-based delivery mechanism to deliver sirolimus to the coronary artery. Sirolimus is a powerful immunosuppressant that helps  prevent  scar tissue from forming around the stent, which can lead to restenosis.  Abluminus NP has been shown in clinical trials to effectively reduce the risk of restenosis. 

3. Silver PTX

 Zilver PTX is a drug-eluting stent that uses a polymer-based delivery mechanism to deliver paclitaxel to the coronary artery. Paclitaxel is a powerful anticancer drug that has been shown to be effective in preventing the formation of scar tissue around the stent.  Zilver PTX has been shown in clinical trials to effectively reduce the risk of restenosis. 

4. Angiolite BTK

 Angiolite BTK is a drug-eluting stent that uses a polymer-based delivery mechanism to deliver a BTK inhibitor into the coronary artery. BTK inhibitors are a new class of drugs that have been shown to be effective in preventing the formation of scar tissue around the stent.  Angiolite BTK is still in clinical trials but  has shown promise in early studies.

THIS REPORT WILL ANSWER FOLLOWING QUESTIONS

1. How many Drug-Eluting Stents are manufactured per annum globally? Who are the sub-component suppliers in different regions?
2. Cost breakup of a Global Drug-Eluting Stents and key vendor selection criteria
3. Where are the Drug-Eluting Stents manufactured? What is the average margin per unit?
4. Market share of Global Drug-Eluting Stents market manufacturers and their upcoming products
5. Cost advantage for OEMs who manufacture Global Drug-Eluting Stents in-house
6. key predictions for next 5 years in Global Drug-Eluting Stents market
7. Average B-2-B Drug-Eluting Stents market price in all segments
8. Latest trends in Drug-Eluting Stents market, by every market segment
9. The market size (both volume and value) of the Drug-Eluting Stents market in 2024-2030 and every year in between?
10. Production breakup of Drug-Eluting Stents market, by suppliers and their OEM relationship.